Michail E. Kalaitzakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michail E. Kalaitzakis has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
R.K.B. Pearce
2 shared publicationsS.M. Gentleman
2 shared publicationsA.J. Walls
1 shared publication- Peixuan Pey
Neuropathology Unit, Division of Brain Sciences, Department of Medicine, Imperial College London, Charing Cross Campus, St Dunstan’s Road, London, UK
1 shared publication R. K. B. Pearce
Neuropathology Unit Division of Brain Sciences Department of Medicine Imperial College London London UK
1 shared publication- Ronald K. B. Pearce
Department of Neuropathology, Division of Neuroscience and Mental Health, Imperial College London, and Hammersmith Hospitals Trust, London, UK
1 shared publication
Latest Publications
- Open Access
- 14 February 2014
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 2 (1) , 21
Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
Microglial activation is a pathological feature common to both Alzheimer’s and Parkinson’s diseases (AD and PD). The classical activation involves release of pro-inflammatory cytokines and reactive oxygen species. This is necessary for maintenance of tissue homeostasis and host defense, but can cause bystander damage when the activation is sustained and uncontrolled. In recent years the heterogeneous nature of microglial activation states in neurodegenerative diseases has become clear and the focus has shifted to alternative activation states that promote tissue maintenance and repair. We studied the distribution of CD163, a membrane-bound scavenger receptor found on perivascular macrophages. CD163 has an immunoregulatory function, and has been found in the parenchyma in other inflammatory diseases e.g. HIV-encephalitis and multiple sclerosis. In this study, we used immunohistochemistry to compare CD163 immunoreactivity in 31 AD cases, 27 PD cases, and 16 control cases. Associations of microglia with pathological hallmarks of AD and PD were investigated using double immunofluorescence.
- 14 February 2014
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 2 (1) , 21
Open AccessPhenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
Microglial activation is a pathological feature common to both Alzheimer’s and Parkinson’s diseases (AD and PD). The classical activation involves release of pro-inflammatory cytokines and reactive oxygen species. This is necessary for maintenance of tissue homeostasis and host defense, but can cause bystander damage when the activation is sustained and uncontrolled. In recent years the heterogeneous nature of microglial activation states in neurodegenerative diseases has become clear and the focus has shifted to alternative activation states that promote tissue maintenance and repair. We studied the distribution of CD163, a membrane-bound scavenger receptor found on perivascular macrophages. CD163 has an immunoregulatory function, and has been found in the parenchyma in other inflammatory diseases e.g. HIV-encephalitis and multiple sclerosis. In this study, we used immunohistochemistry to compare CD163 immunoreactivity in 31 AD cases, 27 PD cases, and 16 control cases. Associations of microglia with pathological hallmarks of AD and PD were investigated using double immunofluorescence.
- 6 February 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (3) , 406
Beyond the limits of detection: Failure of PiB imaging to capture true Aβ burden
- 6 February 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (3) , 406
Beyond the limits of detection: Failure of PiB imaging to capture true Aβ burden
- 30 January 2013
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 39 (6) , 644-653
Disturbed sleep in Parkinson's disease: anatomical and pathological correlates
Aims: Abnormal sleep is a common feature of Parkinson's disease (PD) and prodromal disorders of sleep are frequent (e.g. restless legs syndrome and rapid eye movement sleep behaviour disorder). However, the exact pathological basis of disturbed sleep remains as yet undefined.Methods: To investigate this further, 32 PD cases were stratified into three groups: (1) PD with disturbed sleep, PD(S); (2) PD with dementia (PDD) and disturbed sleep, PDD(S); and (3) PD without disturbed sleep, PD(nS). The extent of α‐synuclein (αSyn) and Alzheimer disease (AD)‐type pathology [amyloid β peptide (Aβ) and tau] was assessed in 15 regions of the PD brain.Results: The results demonstrate a significant association between disturbed sleep in PD and αSyn pathology in specific brainstem [locus coeruleus (P = 0.006) and raphe nuclei (P = 0.02)], hypothalamic [paramammillary nuclei (P = 0.04) and posterior nucleus (P = 0.02)], subcortical/limbic [amygdala (P = 0.03), thalamus (P = 0.01)] and cortical [entorhinal cortex (P = 0.01)] regions. A statistically significant increase of tau pathology was observed in the amygdala (P = 0.03), CA2 sector of the hippocampus (P = 0.01) and entorhinal cortex (P = 0.04) in PD cases with disturbed sleep.Conclusions: Pathological changes in these structures, residing in the brain circuitry relating to sleep physiology, strongly predict the presence of sleep disturbances in PD.
- 30 January 2013
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 39 (6) , 644-653
Disturbed sleep in Parkinson's disease: anatomical and pathological correlates
Aims: Abnormal sleep is a common feature of Parkinson's disease (PD) and prodromal disorders of sleep are frequent (e.g. restless legs syndrome and rapid eye movement sleep behaviour disorder). However, the exact pathological basis of disturbed sleep remains as yet undefined.Methods: To investigate this further, 32 PD cases were stratified into three groups: (1) PD with disturbed sleep, PD(S); (2) PD with dementia (PDD) and disturbed sleep, PDD(S); and (3) PD without disturbed sleep, PD(nS). The extent of α‐synuclein (αSyn) and Alzheimer disease (AD)‐type pathology [amyloid β peptide (Aβ) and tau] was assessed in 15 regions of the PD brain.Results: The results demonstrate a significant association between disturbed sleep in PD and αSyn pathology in specific brainstem [locus coeruleus (P = 0.006) and raphe nuclei (P = 0.02)], hypothalamic [paramammillary nuclei (P = 0.04) and posterior nucleus (P = 0.02)], subcortical/limbic [amygdala (P = 0.03), thalamus (P = 0.01)] and cortical [entorhinal cortex (P = 0.01)] regions. A statistically significant increase of tau pathology was observed in the amygdala (P = 0.03), CA2 sector of the hippocampus (P = 0.01) and entorhinal cortex (P = 0.04) in PD cases with disturbed sleep.Conclusions: Pathological changes in these structures, residing in the brain circuitry relating to sleep physiology, strongly predict the presence of sleep disturbances in PD.
- 1 February 2011
- Published by Elsevier in Neurobiology of Disease
- Vol. 41 (2) , 377-384
Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes
- 1 February 2011
- Published by Elsevier in Neurobiology of Disease
- Vol. 41 (2) , 377-384
Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes
- 1 September 2009
- Published by Elsevier in Neuroscience Letters
- Vol. 461 (1) , 12-15
Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies
- 1 September 2009
- Published by Elsevier in Neuroscience Letters
- Vol. 461 (1) , 12-15
Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies